About UroGen Pharma Ltd.
https://www.urogen.comUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
CEO
Elizabeth A. Barrett
Compensation Summary
(Year 2024)
ETFs Holding This Stock
XSU.TO
Weight:0.03%
Shares:904.79K
IWM
Weight:0.03%
Shares:904.79K
XSXD.L
Weight:0.07%
Shares:338.12K
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Oppenheimer
Outperform
Scotiabank
Sector Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:4.54M
Value:$85.15M
PARADIGM BIOCAPITAL ADVISORS LP
Shares:4.22M
Value:$79.01M
TORONTO DOMINION BANK
Shares:3.19M
Value:$59.79M
Summary
Showing Top 3 of 176
About UroGen Pharma Ltd.
https://www.urogen.comUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.48M ▲ | $51.59M ▲ | $-33.35M ▼ | -121.34% ▼ | $-0.69 ▲ | $-25.77M ▼ |
| Q2-2025 | $0 ▼ | $0 ▼ | $0 ▲ | 0% ▲ | $-1.05 ▼ | $0 ▲ |
| Q1-2025 | $20.25M ▼ | $54.84M ▲ | $-43.84M ▼ | -216.47% ▼ | $-0.92 ▼ | $-38.89M ▼ |
| Q4-2024 | $24.57M ▼ | $49.75M ▲ | $-37.51M ▼ | -152.71% ▼ | $-0.8 ▼ | $-26.49M ▼ |
| Q3-2024 | $25.2M | $40.3M | $-23.67M | -93.93% | $-0.55 | $-14.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $127.03M ▼ | $185.05M ▼ | $300.45M ▼ | $-115.41M ▼ |
| Q2-2025 | $156.95M ▼ | $208.72M ▼ | $302.09M ▲ | $-93.38M ▼ |
| Q1-2025 | $195.89M ▼ | $247.62M ▼ | $294.08M ▼ | $-46.46M ▼ |
| Q4-2024 | $236.69M ▼ | $285.71M ▼ | $294.51M ▲ | $-8.8M ▼ |
| Q3-2024 | $249.57M | $301.94M | $276.43M | $25.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-33.35M ▲ | $-42.27M ▼ | $31.4M ▲ | $8.27M ▲ | $-2.6M ▲ | $-42.36M ▼ |
| Q2-2025 | $-49.94M ▼ | $-39.83M ▲ | $28.41M ▲ | $296K ▲ | $-11.12M ▲ | $-39.97M ▲ |
| Q1-2025 | $-43.84M ▼ | $-42.02M ▼ | $-25.96M ▼ | $34K ▼ | $-67.95M ▼ | $-42.07M ▼ |
| Q4-2024 | $-37.51M ▼ | $-13.62M ▲ | $60.62M ▲ | $71K ▼ | $47.07M ▲ | $-13.73M ▲ |
| Q3-2024 | $-23.67M | $-27.66M | $-106.75M | $39.61M | $-94.81M | $-27.76M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Jelmyto | $50.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
CEO
Elizabeth A. Barrett
Compensation Summary
(Year 2024)
ETFs Holding This Stock
XSU.TO
Weight:0.03%
Shares:904.79K
IWM
Weight:0.03%
Shares:904.79K
XSXD.L
Weight:0.07%
Shares:338.12K
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Oppenheimer
Outperform
Scotiabank
Sector Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:4.54M
Value:$85.15M
PARADIGM BIOCAPITAL ADVISORS LP
Shares:4.22M
Value:$79.01M
TORONTO DOMINION BANK
Shares:3.19M
Value:$59.79M
Summary
Showing Top 3 of 176